Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
1059
Enrollment
INDUSTRY
Sponsor class
Conditions
Migraine
Interventions
DRUG:
Ubrogepant
DRUG:
Placebo-Matching Ubrogepant
Sponsor
AbbVie